Cited by 1,030Genetic Neurodegenerative DiseasesMitochondrial Function and PathologyHereditary Neurological Disorders

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines

Panov, Alexander V., Gutekunst, Claire-Anne, Leavitt, Blair R., Hayden, Michael R., Burke, James R., Strittmatter, Warren J., Greenamyre, J. Timothy·2002·Nature Neuroscience

DOI 10.1038/nn884

Open this paper in CoChat — free account

Abstract

Huntington's disease (HD) is caused by an expansion of exonic CAG triplet repeats in the gene encoding huntingtin protein (Htt), but the mechanisms by which this mutant protein causes neurodegeneration remain unknown. Here we show that lymphoblast mitochondria from patients with HD have a lower membrane potential and depolarize at lower calcium loads than do mitochondria from controls. We found a similar defect in brain mitochondria from transgenic mice expressing full-length mutant huntingtin, and this defect preceded the onset of pathological or behavioral abnormalities by months. By electron microscopy, we identified N-terminal mutant huntingtin on neuronal mitochondrial membranes, and by incubating normal mitochondria with a fusion protein containing an abnormally long polyglutamine repeat, we reproduced the mitochondrial calcium defect seen in human patients and transgenic animals. Thus, mitochondrial calcium abnormalities occur early in HD pathogenesis and may be a direct effect of mutant huntingtin on the organelle.

Integrity signals

Registry

Crossref · 10.1038/nn884

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R. S., Sherer, T., MacKenzie, G. M., Garcia‐Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,770
Self-citation
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.
Shah, M. A., Datson, N. A., Srinidhi, L., Stanton, V. P., MacDonald, M. E., Allard, M. W., Youngman, S., Am, F., Mott, R., Draths, K., et al. (1993) · Cell · Cited by 3,055
Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain
DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., & Aronin, N. (1997) · Science · doi:10.1126/science.277.5334.1990 · Cited by 2,439
Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation
Davies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., & Bates, G. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80513-9 · Cited by 2,188
Mitochondrial Transport of Cations: Channels, Exchangers, and Permeability Transition
Bernardi, P. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1127 · Cited by 1,546
Aging, energy, and oxidative stress in neurodegenerative diseases
Beal, M. F. (1995) · Annals of Neurology · doi:10.1002/ana.410380304 · Cited by 1,434
Huntingtin-Encoded Polyglutamine Expansions Form Amyloid-like Protein Aggregates In Vitro and In Vivo
Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., Bates, G. P., Davies, S. W., Lehrach, H., & Wanker, E. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80514-0 · Cited by 1,291 · cited 1×
“Consistent with the toxic 'gain-of-function' hypothesis, mutant Htt self-associates and forms aggregates in a polyglutamine length–dependent manne”
Background
Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y.-Z., Greenwald, M., et al. (2001) · Nature · doi:10.1038/35099568 · Cited by 1,228
Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease
Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B. R., Goffredo, D., Conti, L., MacDonald, M. E., Friedlander, R. M., Silani, V., Hayden, M. R., et al. (2001) · Science · doi:10.1126/science.1059581 · Cited by 1,123
Self-citation

Flagged first, then by citations

Show all 35 references

Sorted by citations

Items 101–200 of 1,000

Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone
Fleming, S. M. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.01.023 · Cited by 230
Pathogenesis of polyglutamine disorders: aggregation revisited
Michalik, A., & Broeckhoven, C. V. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg295 · Cited by 235
Mitochondrial trafficking and morphology in healthy and injured neurons
Chang, D. T. W., & Reynolds, I. J. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.09.003 · Cited by 235
Mitochondria as a Therapeutic Target for Aging and Neurodegenerative Diseases
Reddy, P. H., & Reddy, T. P. (2011) · Current Alzheimer Research · doi:10.2174/156720511795745401 · Cited by 233
Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington’s disease patients
Chen, C., Wu, Y., Cheng, M., Liu, J., Lee, Y., Lee, P.-W., Soong, B., & Chiu, D. T.-Y. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.05.093 · Cited by 226
Inhibition of mitochondrial protein import by mutant huntingtin
Yano, H., Baranov, S. V., Baranova, O. V., Kim, J., Pan, Y., Yablonska, S., Carlisle, D. L., Ferrante, R. J., Kim, A. H., & Friedlander, R. M. (2014) · Nature Neuroscience · doi:10.1038/nn.3721 · Cited by 226
Melatonin in Alzheimer's disease and other neurodegenerative disorders
Srinivasan, V. J., Pandi-Perumal, S. R., Cardinali, D. P., Pöeggeler, B., & Hardeland, R. (2006) · Behavioral and Brain Functions · doi:10.1186/1744-9081-2-15 · Cited by 229
Gradual Alteration of Mitochondrial Structure and Function by β-Amyloids: Importance of Membrane Viscosity Changes, Energy Deprivation, Reactive Oxygen Species Production, and Cytochrome c Release
Aleardi, A. M., Benard, G., Augereau, O., Malgat, M., Talbot, J.-C., Mazat, J., Letellier, T., Dachary-Prigent, J., Solaini, G., & Rossignol, R. (2005) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-005-6631-3 · Cited by 227
Huntington’s disease: from huntingtin function and dysfunction to therapeutic strategies
Borrell-Pagés, M., Zala, D., Humbert, S., & Saudou, F. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6242-0 · Cited by 241
Experimental therapeutics in transgenic mouse models of Huntington's disease
Beal, M. F., & Ferrante, R. J. (2004) · Nature reviews. Neuroscience · doi:10.1038/nrn1386 · Cited by 227
PGC-1α, mitochondrial dysfunction, and Huntington's disease
Johri, A., Chandra, A., & Beal, M. F. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.04.016 · Cited by 227
Effects of overexpression of Huntingtin proteins on mitochondrial integrity
Wang, H., Lim, P. J., Karbowski, M., & Monteiro, M. J. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn404 · Cited by 222
Energy deficit in Huntington disease: why it matters
Mochel, F., & Haller, R. G. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45691 · Cited by 220
Metformin therapy in a transgenic mouse model of Huntington's disease
Ma, T. C., Buescher, J. L., Oatis, B., Funk, J. A., Nash, A. J., Carrier, R. L., & Hoyt, K. R. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.10.039 · Cited by 224
Pathological Cell-Cell Interactions Elicited by a Neuropathogenic Form of Mutant Huntingtin Contribute to Cortical Pathogenesis in HD Mice
Gu, X., Li, C., Wei, W., Lo, V., Gong, S., Li, S.-H., Iwasato, T., Itohara, S., Li, X., Módy, I., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.03.025 · Cited by 222
Neuronal Apoptosis in Neurodegeneration
Okouchi, M., Ekshyyan, O. Y., Maracine, M., & Aw, T. Y. (2007) · Antioxidants and Redox Signaling · doi:10.1089/ars.2007.1511 · Cited by 222
trans-(−)-ε-Viniferin Increases Mitochondrial Sirtuin 3 (SIRT3), Activates AMP-activated Protein Kinase (AMPK), and Protects Cells in Models of Huntington Disease
Fu, J., Jin, J., Cichewicz, R. H., Hageman, S. A., Ellis, T. K., Xiang, L., Peng, Q., Jiang, M., Arbez, N., Hotaling, K., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.382226 · Cited by 213
Excitotoxic Neuronal Death and the Pathogenesis of Huntington's Disease
Estrada‐Sánchez, A. M., Mejía-Toiber, J., & Massieu, L. (2008) · Archives of Medical Research · doi:10.1016/j.arcmed.2007.11.011 · Cited by 213
Mitochondrial calcium function and dysfunction in the central nervous system
Nicholls, D. G. (2009) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2009.03.010 · Cited by 213
Mitochondrial Cyclic AMP Response Element-binding Protein (CREB) Mediates Mitochondrial Gene Expression and Neuronal Survival
Lee, J.-H., Kim, C., Simon, D. K., Aminova, L. R., Andreyev, A. Y., Kushnareva, Y. E., Murphy, A. N., Lonze, B. E., Kim, K. S., Ginty, D. D., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500140200 · Cited by 218
FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease
Jin, K., LaFevre-Bernt, M. A., Sun, Y., Chen, S., Gafni, J., Crippen, D., Logvinova, A. V., Ross, C. A., Greenberg, D. A., & Ellerby, L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506375102 · Cited by 212
Neuronal Cells Rearrangement During Aging and Neurodegenerative Disease: Metabolism, Oxidative Stress and Organelles Dynamic
Castelli, V., Benedetti, E., Antonosante, A., Catanesi, M., Pitari, G., Ippoliti, R., Cimini, A., & d’Angelo, M. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00132 · Cited by 224
Mitochondrial Dysfunction in Huntington’s Disease
Carmo, C., Naia, L., Lopes, C., & Rego, A. C. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-71779-1_3 · Cited by 214
Dopaminergic Signaling and Striatal Neurodegeneration in Huntington's Disease
Tang, T.-S., Chen, X., Liu, J., & Борисович, Б. И. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.1396-07.2007 · Cited by 207
Regulation of ER-mitochondria contacts by Parkin via Mfn2
Basso, V., Marchesan, E., Peggion, C., Chakraborty, J., von Stockum, S., Giacomello, M., Ottolini, D., Debattisti, V., Caicci, F., Tasca, E., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.006 · Cited by 217
The role of mitochondrial dysfunction in age-related diseases
Lane, R. K., Hilsabeck, T., & Rea, S. L. (2015) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2015.05.021 · Cited by 205
Mitochondria in Neurodegeneration
Lezi, E., & Swerdlow, R. H. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-2869-1_12 · Cited by 213
Calcium and Cell Death: The Mitochondrial Connection
Bernardi, P., & Rasola, A. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6191-2_18 · Cited by 209
Mutant HTT (huntingtin) impairs mitophagy in a cellular model of Huntington disease
Franco-Iborra, S., Plaza‐Zabala, A., Montpeyó, M., Sebastián, D., Vila, M., & Martínez‐Vicente, M. (2020) · Autophagy · doi:10.1080/15548627.2020.1728096 · Cited by 205
VCP recruitment to mitochondria causes mitophagy impairment and neurodegeneration in models of Huntington’s disease
Guo, X., Sun, X., Hu, D., Wang, Y.-J., Fujioka, H., Vyas, R., Chakrapani, S., Joshi, A. U., Luo, Y., Mochly-Rosen, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms12646 · Cited by 200
Mitochondria-associated membranes as hubs for neurodegeneration
Krols, M., Isterdael, G. V., Asselbergh, B., Kremer, A., Lippens, S., Timmerman, V., & Janssens, S. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1528-7 · Cited by 210
New Avenues for the Treatment of Huntington’s Disease
Kim, A. M., Lalonde, K. M., Truesdell, A., Welter, P. G., Brocardo, P. S., Rosenstock, T. R., & Gil‐Mohapel, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168363 · Cited by 217
A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease
Mastroberardino, P. G., Hoffman, E. K., Horowitz, M. P., Betarbet, R., Taylor, G., Cheng, D., Na, H. M., Gutekunst, C.-A., Gearing, M., Trojanowski, J. Q., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.02.009 · Cited by 195
Self-citation
Chemotherapy for the Brain: The Antitumor Antibiotic Mithramycin Prolongs Survival in a Mouse Model of Huntington's Disease
Ferrante, R. J., Ryu, H., Kubilus, J. K., D’Mello, S. R., Sugars, K. L., Lee, J.-H., Lu, P., Smith, K., Browne, S. E., Beal, M. F., et al. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.2599-04.2004 · Cited by 195
Mitochondrial Quality Control in Neurodegenerative Diseases: Focus on Parkinson's Disease and Huntington's Disease
Franco-Iborra, S., Vila, M., & Perier, C. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00342 · Cited by 197
Reactive oxygen/nitrogen species and their functional correlations in neurodegenerative diseases
Ramalingam, M., & Kim, S. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-011-0758-7 · Cited by 194
Calcium Homeostasis and Mitochondrial Dysfunction in Striatal Neurons of Huntington Disease
Lim, D., Fedrizzi, L., Tartari, M., Zuccato, C., Cattaneo, E. F., Brini, M., & Carafoli, E. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704704200 · Cited by 194
Generalized brain and skin proteasome inhibition in Huntington’s disease
Seo, H., Sonntag, K., & Isacson, O. (2004) · Annals of Neurology · doi:10.1002/ana.20207 · Cited by 188
Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease
Reddy, P. H., & Shirendeb, U. P. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.016 · Cited by 188
Genetic modifiers of the phenotype of mice deficient in mitochondrial superoxide dismutase
Huang, T., Naeemuddin, M., Elchuri, S. V., Yamaguchi, M., Kozy, H. M., Carlson, E. J., & Epstein, C. J. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl034 · Cited by 188
Amyloid Peptide Channels
Kagan, B. L., Azimov, R., & Azimova, R. (2004) · The Journal of Membrane Biology · doi:10.1007/s00232-004-0709-4 · Cited by 195
Mitochondrial DNA damage and repair in neurodegenerative disorders
Yang, J., Weissman, L., Bohr, V. A., & Mattson, M. P. (2008) · DNA repair · doi:10.1016/j.dnarep.2008.03.012 · Cited by 187
Huntingtin Bodies Sequester Vesicle-Associated Proteins by a Polyproline-Dependent Interaction
Qin, Z., Wang, Y., Sapp, E., Cuiffo, B., Wanker, E. E., Hayden, M. R., Kegel, K. B., D, N. A. M., & DiFiglia, M. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.1409-03.2004 · Cited by 185
Self-citation
Mitochondria, calcium-dependent neuronal death and neurodegenerative disease
Duchen, M. R. (2012) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-012-1112-0 · Cited by 191
Proteomic Analysis of Protein Expression and Oxidative Modification in R6/2 Transgenic Mice
Marzia Perluigi, A., Poon, H. F., Maragos, W. F., Pierce, W. M. J., Klein, J. B., Calabrese, V., Cini, C., Marco, C. M. D., & Butterfield, D. A. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500090-mcp200 · Cited by 184
Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease
Carsten Saft, C., Zange, J., Andrich, J., Müller, K., Lindenberg, K. S., Landwehrmeyer, G. B., Vorgerd, M., Kraus, P. H., Przuntek, H., & Schöls, L. J. (2005) · Movement Disorders · doi:10.1002/mds.20373 · Cited by 184
The role of mitochondria in inherited neurodegenerative diseases
Kwong, J. Q., Beal, M. F., & Manfredi, G. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03990.x · Cited by 180
Mitochondrial Fission in Human Diseases
Serasinghe, M. N., & Chipuk, J. E. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_38 · Cited by 186
The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies
Bauer, P. O., & Nukina, N. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06302.x · Cited by 178
Mitochondria and Huntington's Disease Pathogenesis: Insight from Genetic and Chemical Models
Browne, S. E. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.018 · Cited by 176
Iron Accumulates in Huntington’s Disease Neurons: Protection by Deferoxamine
Chen, J., Marks, E. S., Lai, B. C. H., Zhang, Z., Duce, J. A., Lam, L. Q., Volitakis, I., Bush, A. I., Hersch, S. M., & Fox, J. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077023 · Cited by 176
Increased Susceptibility of Striatal Mitochondria to Calcium-Induced Permeability Transition
Brustovetsky, N., Brustovetsky, T., Purl, K. J., Capano, M., Crompton, M., & Dubinsky, J. M. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-12-04858.2003 · Cited by 179
Huntington's disease: The current state of research with peripheral tissues
Sassone, J., Colciago, C., Cislaghi, G., Silani, V., & Ciammola, A. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.05.012 · Cited by 175
Mitophagy and age-related pathologies: Development of new therapeutics by targeting mitochondrial turnover
Palikaras, K., Daskalaki, I., Markaki, M., & Tavernarakis, N. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.04.005 · Cited by 181
Neuroinflammation in Huntington’s disease
Möller, T. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0430-7 · Cited by 180
Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease
Quintanilla, R. A., & Johnson, G. V. W. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.07.010 · Cited by 176
Quercetin supplementation is effective in improving mitochondrial dysfunctions induced by 3-nitropropionic acid: Implications in Huntington's disease
Sandhir, R., & Mehrotra, A. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.11.018 · Cited by 171
Differential vulnerability of neurons in Huntington’s disease: the role of cell type‐specific features
Han, I., You, Y., Kordower, J. H., Brady, S. T., & Morfini, G. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06672.x · Cited by 176
Modulation of lipid peroxidation and mitochondrial function improves neuropathology in Huntington’s disease mice
Lee, J.-H., Kosaras, B., Signore, S. J. D., Cormier, K., McKee, A. C., Ratan, R. R., Kowall, N. W., & Ryu, H. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0788-5 · Cited by 170
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice
Dedeoglu, A., Kubilus, J. K., Yang, L., Ferrante, K. L., Hersch, S. M., Beal, M. F., & Ferrante, A. R. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01706.x · Cited by 169
Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease
Zeron, M. M., Fernandes, H. B., Krebs, C., Shehadeh, J., Wellington, C. L., Leavitt, B. R., Baimbridge, K. G., Hayden, M. R., & Raymond, L. A. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2003.11.014 · Cited by 170
Self-citation
Evidence of Oxidant Damage in Huntington's Disease: Translational Strategies Using Antioxidants
Stack, E. C., Matson, W. R., & Ferrante, R. J. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.008 · Cited by 169
Redox Proteomics in Selected Neurodegenerative Disorders: From Its Infancy to Future Applications
Butterfield, D. A., Marzia Perluigi, A., Reed, T. T., Muharib, T., Hughes, C. P., Robinson, R. A. S., & Rukhsana Sultana, A. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4109 · Cited by 171
The mitochondrial permeability transition in neurologic disease
Norenberg, M. D., & RAO, K. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.02.008 · Cited by 168
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice
Guidetti, P., Bates, G. P., Graham, R. K., Hayden, M. R., Leavitt, B. R., MacDonald, M. E., Slow, E., Wheeler, V. C., Woodman, B., & Schwarcz, R. M. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.02.011 · Cited by 166
Self-citation
Huntington's Disease and the Striatal Medium Spiny Neuron: Cell-Autonomous and Non-Cell-Autonomous Mechanisms of Disease
Ehrlich, M. E. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0112-2 · Cited by 170
Akt is altered in an animal model of Huntington's disease and in patients
Colin, E., Régulier, E., Perrin, V., Dürr, A., Brice, A., Aebischer, P., Déglon, N., Humbert, S., & Saudou, F. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.03985.x · Cited by 164
Enhanced caffeine‐induced Ca2+release in the 3xTg‐AD mouse model of Alzheimer's disease
Smith, I. F., Hitt, B. D., Green, K. N., Oddo, S., & LaFerla, F. M. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03332.x · Cited by 164
Nature and cause of mitochondrial dysfunction in Huntington’s disease: focusing on huntingtin and the striatum
Oliveira, J. M. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06741.x · Cited by 163
Selective Neuronal Degeneration in Huntington's Disease
Cowan, C. M., & Raymond, L. A. (2006) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(06)75002-5 · Cited by 166
Calpain Is a Major Cell Death Effector in Selective Striatal Degeneration InducedIn Vivoby 3-Nitropropionate: Implications for Huntington's Disease
Bizat, N., Hermel, J., Boyer, F., Jacquard, C., Créminon, C., Ouary, S., Escartin, C., Hantraye, P., Krajewski, S., & Brouillet, E. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-12-05020.2003 · Cited by 163
Interaction of Mitochondrial Calcium and ROS in Neurodegeneration
Baev, A. Y., Vinokurov, A. Y., Novikova, I. N., Dremin, V. V., Potapova, E. V., & Abramov, A. Y. (2022) · Cells · doi:10.3390/cells11040706 · Cited by 162
Therapeutic approaches to Huntington disease: from the bench to the clinic
Caron, N. S., Dorsey, E. R., & Hayden, M. R. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.133 · Cited by 168
Self-citation
Mechanism of ER Stress-Induced Brain Damage by IP3 Receptor
Higo, T., Hamada, K., Hisatsune, C., Nukina, N., Hashikawa, T., Hattori, M., Nakamura, T., & Mikoshiba, K. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.010 · Cited by 160
Gene expression in Huntington's disease skeletal muscle: a potential biomarker
Strand, A. D., Aragaki, A. K., Shaw, D., Bird, T. D., Holton, J. L., Turner, C., Tapscott, S. J., Tabrizi, S. J., Schapira, A. H. V., Kooperberg, C. L., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi192 · Cited by 160
Mitochondrial structural and functional dynamics in Huntington's disease
Reddy, P. H., Mao, P., & Mańczak, M. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.04.001 · Cited by 164
Shaping the role of mitochondria in the pathogenesis of Huntington's disease
Costa, V., & Scorrano, L. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.65 · Cited by 162
Potential role of mitochondria-associated endoplasmic reticulum membrane proteins in diseases
Mao, H. Z., Chen, W., Chen, L., & Li, L. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115011 · Cited by 164
Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson’s disease by disturbing calcium flux
Marongiu, R., Spencer, B. J., Crews, L. A., Adame, A., Patrick, C., Trejo, M., Dallapiccola, B., Valente, E. M., & Masliah, E. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05932.x · Cited by 157
Brain mitochondrial iron accumulates in Huntington's disease, mediates mitochondrial dysfunction, and can be removed pharmacologically
Agrawal, S., Fox, J. A., Thyagarajan, B., & Fox, J. H. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.04.002 · Cited by 155
Mitochondrial abnormalities in spinal and bulbar muscular atrophy
Ranganathan, S., Harmison, G. G., Meyertholen, K., Pennuto, M., Burnett, B. G., & Fischbeck, K. H. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn310 · Cited by 154
Mitochondrial iron homeostasis and its dysfunctions in neurodegenerative disorders
Mena, N. P., Urrutia, P. J., Lourido, F., Carrasco, C. M., & Núñez, M. T. (2015) · Mitochondrion · doi:10.1016/j.mito.2015.02.001 · Cited by 154
The Role of the Antioxidant Response in Mitochondrial Dysfunction in Degenerative Diseases: Cross-Talk between Antioxidant Defense, Autophagy, and Apoptosis
Huang, M., Chiang, S., Kalinowski, D. S., Bae, D.-H., Sahni, S., & Richardson, D. R. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/6392763 · Cited by 155
Metabolic Reprogramming in Astrocytes Distinguishes Region-Specific Neuronal Susceptibility in Huntington Mice
Polyzos, A. A., Lee, D. Y., Datta, R., Hauser, M., Budworth, H., Holt, A., Mihalik, S. J., Goldschmidt, P., Frankel, K. A., Trego, K. S., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.03.004 · Cited by 152
Polyglutamine Diseases: Where does Toxicity Come from? What is Toxicity? Where are We Going?
Takahashi, T., Katada, S., & Onodera, O. (2010) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjq005 · Cited by 157
Formation of Polyglutamine Inclusions in a Wide Range of Non-CNS Tissues in the HdhQ150 Knock-In Mouse Model of Huntington's Disease
Moffitt, H., McPhail, G., Woodman, B., Hobbs, C., & Bates, G. P. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008025 · Cited by 151
Mitochondrial DNA damage Is associated with reduced mitochondrial bioenergetics in Huntington's disease
Siddiqui, A., Rivera, S., Castro, M. D. R., Acevedo‐Torres, K., Rane, A., Torres‐Ramos, C. A., Nicholls, D. G., Andersen, J. K., & Ayala‐Torres, S. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.06.008 · Cited by 154
Mouse models of Huntington's disease and methodological considerations for therapeutic trials
Ferrante, R. J. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.04.001 · Cited by 157
Huntington’s Disease and Mitochondria
Farshbaf, M. J., & Ghaedi, K. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9766-1 · Cited by 153
Mitochondrial fission in Huntington's disease mouse striatum disrupts ER-mitochondria contacts leading to disturbances in Ca2+ efflux and Reactive Oxygen Species (ROS) homeostasis
Cherubini, M., López-Molina, L., & Ginés, S. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104741 · Cited by 148
Nitric oxide regulates mitochondrial oxidative stress protection via the transcriptional coactivator PGC‐1α
Borniquel, S., Valle, I., Cadenas, S., Lamas, S., & Monsalve, M. (2006) · The FASEB Journal · doi:10.1096/fj.05-5189fje · Cited by 151
Role of p53 in Neurodegenerative Diseases
Chang, J. R., Ghafouri, M., Mukerjee, R., Bagashev, A., Chabrashvili, T., & Sawaya, B. E. (2011) · Neurodegenerative Diseases · doi:10.1159/000329999 · Cited by 149
The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin
Rangone, H., Poizat, G., Troncoso, J., Ross, C. A., MacDonald, M. E., Saudou, F., & Humbert, S. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2003.03131.x · Cited by 144
Neuronal Store-Operated Calcium Entry Pathway as a Novel Therapeutic Target for Huntington's Disease Treatment
Wu, J., Shih, H.-P., Vigont, V. A., Hrdlicka, L., Diggins, L. T., Singh, C. M., Mahoney, M. B., Chesworth, R., Shapiro, G., Zimina, O. A., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.04.012 · Cited by 143
Mechanisms of protein toxicity in neurodegenerative diseases
Chung, C. G., Lee, H., & Lee, S. B. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2854-4 · Cited by 142
Role of oxidative DNA damage in mitochondrial dysfunction and Huntington’s disease pathogenesis
Ayala‐Peña, S. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.04.017 · Cited by 147
The Clinical and Genetic Features of Huntington Disease
Sturrock, A., & Leavitt, B. R. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710383573 · Cited by 144
Self-citation
Mutant Huntingtin Expression Induces Mitochondrial Calcium Handling Defects in Clonal Striatal Cells
Milakovic, T., Quintanilla, R. A., & Johnson, G. V. W. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603845200 · Cited by 142
Exosomes from adipose‐derived stem cells ameliorate phenotype of Huntington's disease in vitro model
Lee, M., Liu, T., Im, W., & Kim, M. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13275 · Cited by 141
Mutant huntingtin impairs Ku70-mediated DNA repair
Enokido, Y., Tamura, T., Ito, H., Arumughan, A., Komuro, A., Shiwaku, H., Sone, M., Foulle, R., Sawada, H., Ishiguro, H., et al. (2010) · The Journal of Cell Biology · doi:10.1083/jcb.200905138 · Cited by 144

Authors: Panov, A. V., Gutekunst, C.-A., Leavitt, B. R., Hayden, M. R., Burke, J. R., Strittmatter, W. J., & Greenamyre, J. T.
Affiliations: Emory University (US)
University of British Columbia (CA)
Duke Medical Center (US)
Corresponding author: Greenamyre, J. Timothy
ORCID: Panov, Alexander V.
Gutekunst, Claire-Anne
Leavitt, Blair R.
Hayden, Michael R.
Burke, James R.
Greenamyre, J. Timothy
Venue: Nature Neuroscience
Publisher: Springer Science and Business Media LLC
Published: 2002-07-01
Volume: 5
Issue: 8
Pages: 731-736
ISSN: 1097-6256 (ISSN-L)
1546-1726
DOI: 10.1038/nn884
OpenAlex: W1972771185
Cited by: 1,030
References: 35
Citations by year: 2026: 16 · 2025: 23 · 2024: 26 · 2023: 27 · 2022: 30 · 2021: 49 · 2020: 29 · 2019: 35 · 2018: 39 · 2017: 23 · 2016: 45 · 2015: 35 · 2014: 48 · 2013: 33 · 2012: 68
FWCI: 19.24
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Neuroscience (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5r01ag014648-05)
National Institute on Aging (AG14648)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
Keywords: Huntington's disease, mitochondrial calcium handling, polyglutamine expansion, mutant huntingtin, mitochondrial membrane potential, mitochondrial depolarization, neurodegeneration, transgenic mice, early pathogenesis
MeSH terms: Huntingtin Protein, Animals, Brain, Brain Chemistry, Calcium, Cell Line, Disease Models, Animal, Humans, Huntington Disease, Intracellular Membranes, Lymphocytes, Membrane Potentials, Mice, Transgenic, Microscopy, Electron, Mitochondria, Nerve Tissue Proteins, Nuclear Proteins, Recombinant Fusion Proteins, Trinucleotide Repeat Expansion, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks